Canada Pension Plan Investment Board Purchases New Holdings in Elanco Animal Health Incorporated $ELAN

Key Points

• Canada Pension Plan Investment Board purchased 51,700 shares of Elanco Animal Health during the second quarter, worth approximately $1.27 million. Institutional investors collectively own 97.48% of the company.
• Elanco exceeded quarterly expectations, reporting $0.34 EPS versus the $0.27 consensus and $1.37 billion in revenue, up 10.2% year over year. The company guided for full-year 2026 EPS of $1.10–$1.16.
• Analyst sentiment remains generally positive, with a “Moderate Buy” consensus and an average price target of $29.09 versus the stock’s reported $24.01 price. Company directors also purchased a combined 45,000 shares recently.

Canada Pension Plan Investment Board purchased a new position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 51,700 shares of the company's stock, valued at approximately $1,272,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. NewEdge Advisors LLC lifted its stake in shares of Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock worth $25,000 after buying an additional 627 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Elanco Animal Health in the 2nd quarter worth about $38,000. Root Financial Partners LLC increased its holdings in Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock worth $40,000 after buying an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. purchased a new position in Elanco Animal Health in the 4th quarter worth about $41,000. Finally, Bessemer Group Inc. lifted its stake in Elanco Animal Health by 33.2% during the 1st quarter. Bessemer Group Inc. now owns 2,105 shares of the company's stock valued at $50,000 after acquiring an additional 525 shares during the period. Hedge funds and other institutional investors own 97.48% of the company's stock.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $24.01 on Tuesday. The business has a 50-day simple moving average of $24.62 and a two-hundred day simple moving average of $23.99. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. Elanco Animal Health Incorporated has a 52 week low of $17.11 and a 52 week high of $27.98. The stock has a market cap of $12.00 billion, a price-to-earnings ratio of -58.56, a PEG ratio of 1.44 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same period in the previous year, the company posted $0.26 EPS. The firm's revenue was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Insider Activity

In other news, Director Lawrence Erik Kurzius bought 40,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were bought at an average price of $23.40 per share, for a total transaction of $936,000.00. Following the purchase, the director owned 188,647 shares in the company, valued at $4,414,339.80. This represents a 26.91% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Michael J. Harrington purchased 5,000 shares of the business's stock in a transaction on Wednesday, August 12th. The stock was acquired at an average price of $21.82 per share, with a total value of $109,100.00. Following the purchase, the director directly owned 131,451 shares in the company, valued at $2,868,260.82. This represents a 3.95% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders purchased 63,198 shares of company stock worth $1,473,109. 1.14% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ELAN. KeyCorp boosted their price objective on shares of Elanco Animal Health from $29.00 to $30.00 and gave the company an "overweight" rating in a report on Thursday, August 6th. JPMorgan Chase & Co. boosted their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an "overweight" rating in a research note on Thursday, May 7th. Weiss Ratings downgraded Elanco Animal Health from a "sell (d+)" rating to a "sell (d)" rating in a research note on Thursday, August 20th. Piper Sandler reissued an "overweight" rating on shares of Elanco Animal Health in a report on Monday, June 29th. Finally, UBS Group boosted their price target on Elanco Animal Health from $31.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Elanco Animal Health currently has an average rating of "Moderate Buy" and an average target price of $29.09.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source